Coeptis Therapeutics (NASDAQ:ZSQR) Shares Up 13.4% – Here’s What Happened

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s share price shot up 13.4% during trading on Monday . The company traded as high as $12.40 and last traded at $12.40. 229,908 shares changed hands during mid-day trading, an increase of 115% from the average session volume of 106,765 shares. The stock had previously closed at $10.93.

Analyst Ratings Changes

Separately, Wall Street Zen cut shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Coeptis Therapeutics Stock Up 16.8%

The company has a current ratio of 3.25, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $656.76 million, a price-to-earnings ratio of -5.07 and a beta of -0.22. The firm’s 50 day simple moving average is $11.89 and its 200-day simple moving average is $12.93.

Coeptis Therapeutics (NASDAQ:ZSQR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%. The firm had revenue of $0.11 million during the quarter.

Institutional Investors Weigh In On Coeptis Therapeutics

A number of large investors have recently added to or reduced their stakes in ZSQR. Marshall Wace LLP acquired a new stake in Coeptis Therapeutics in the 4th quarter valued at about $259,000. Yorkville Advisors Global LP acquired a new stake in Coeptis Therapeutics in the 3rd quarter valued at about $140,000. State Street Corp lifted its holdings in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after purchasing an additional 6,962 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its holdings in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares in the last quarter. 13.88% of the stock is owned by institutional investors and hedge funds.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.